These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Factors predicting survival after transjugular intrahepatic portosystemic shunt creation: 15 years' experience from a single tertiary medical center. Pan JJ; Chen C; Caridi JG; Geller B; Firpi R; Machicao VI; Hawkins IF; Soldevila-Pico C; Nelson DR; Morelli G J Vasc Interv Radiol; 2008 Nov; 19(11):1576-81. PubMed ID: 18789725 [TBL] [Abstract][Full Text] [Related]
12. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Russo MW; Sood A; Jacobson IM; Brown RS Am J Gastroenterol; 2003 Nov; 98(11):2521-7. PubMed ID: 14638358 [TBL] [Abstract][Full Text] [Related]
13. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Wong F; Pantea L; Sniderman K Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086 [TBL] [Abstract][Full Text] [Related]
14. Older patient age may predict early mortality after transjugular intrahepatic portosystemic shunt creation in individuals at intermediate risk. Parvinian A; Shah KD; Couture PM; Minocha J; Knuttinen MG; Bui JT; Gaba RC J Vasc Interv Radiol; 2013 Jul; 24(7):941-6. PubMed ID: 23707226 [TBL] [Abstract][Full Text] [Related]
15. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219 [TBL] [Abstract][Full Text] [Related]
16. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. Rössle M; Ochs A; Gülberg V; Siegerstetter V; Holl J; Deibert P; Olschewski M; Reiser M; Gerbes AL N Engl J Med; 2000 Jun; 342(23):1701-7. PubMed ID: 10841872 [TBL] [Abstract][Full Text] [Related]
17. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. Arroyo V; Terra C; Ginès P J Hepatol; 2007 May; 46(5):935-46. PubMed ID: 17391801 [No Abstract] [Full Text] [Related]
18. Prognostic value of hepatocyte proliferative activity after transjugular intrahepatic portosystemic shunt. Delhaye M; Le Moine O; Degraef C; Devière J; Galand P Am J Gastroenterol; 2001 Jun; 96(6):1866-71. PubMed ID: 11419841 [TBL] [Abstract][Full Text] [Related]